

Annexure 4: Cannabidiol (CBD)

23 March 2021

GUIDELINE 7.06: COMPLEMENTARY MEDICINES – GUIDANCE ON SPECIFIED SUBSTANCES

To all stakeholders

The purpose of Guideline 7.06 (*Complementary Medicines – Guidance on specified substances*) is to provide guidance to applicants on the use of specified substances in Complementary Medicines and their further application for registration.

Following the amendments to the Schedules as published on the 22 May 2020, SAHPRA intended to develop and publish guidance on the use of Cannabidiol as a specified substance used in Complementary Medicines and list Cannabidiol in annexures to Guideline 7.06 bearing in mind any limitations imposed by the Schedule inscription for CBD.

In assessing the safety, efficacy and quality of Cannabidiol (CBD) the attached Annexure has been developed to guide the use of the substances listed therein when used in Complementary Medicines as Health Supplements. The attached Annexure 4: Cannabidiol (CBD) to the Guideline 7.06 is now published for comment.

Interested persons are invited to submit any substantiated comments, in writing on the proposed annexures within **THREE (3) months** from date of publication by submission of comment related to this guidelines on the SAHPRA CM portal (www.sahpracm.org.za – “Guidelines” – “Documents for comment”) utilising the comment template issued for this purpose.

DocuSigned by:

Boitumelo Semete-Makokotlela

DR BOITUMELO SEMETE-MAKOKOTLELA
CEO: SAHPRA

24 March 2021